Intellia Therapeutics (NASDAQ:NTLA) Price target raised to $101.00 by Credit Suisse Group analysts


Intellia Therapeutics (NASDAQ:NTLA – Get a review) had its price target raised by Credit Suisse Group research analysts to $101.00 in a note issued to investors on Tuesday, Stock Target Advisor reports. Credit Suisse Group’s price target indicates upside potential of 71.56% from the company’s current price.

NTLA has been the subject of a number of other research reports. BMO Capital Markets began covering Intellia Therapeutics in a report on Thursday, June 16. They issued a “market performance” rating and a target price of $54.00 for the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday. JMP Securities lowered its target price on Intellia Therapeutics from $165.00 to $110.00 in a Monday, May 9 report. SVB Leerink cut its price target on Intellia Therapeutics from $155.00 to $152.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Oppenheimer reduced its price target on Intellia Therapeutics from $160.00 to $130.00 in a Monday, May 9 research report. One research analyst has assigned the stock a sell rating, one has assigned a hold rating and fifteen have assigned the company’s stock a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.00.

Intellia Therapeutics Price Performance

NTLA shares traded at $4.62 at midday on Tuesday, hitting $58.87. 23,989 shares of the company were traded, against an average volume of 1,242,258. The company’s 50-day simple moving average is $55.72 and its 200-day simple moving average is $63.83 . Intellia Therapeutics has a 52-week low of $37.08 and a 52-week high of $180.59. The stock has a market capitalization of $4.47 billion, a PE ratio of -11.05 and a beta of 2.00.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last released quarterly earnings data on Thursday, August 4. The company reported ($1.33) earnings per share for the quarter, missing analyst consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 38.74%. The company posted revenue of $14.00 million in the quarter, compared to $9.50 million expected by analysts. In the same quarter last year, the company made ($1.01) earnings per share. The company’s quarterly revenue increased 115.4% year over year. Equity research analysts expect Intellia Therapeutics to post -5.77 earnings per share for the current year.

Institutional entries and exits

A number of hedge funds have recently changed their positions in NTLA. ARK Investment Management LLC increased its equity stake in Intellia Therapeutics by 13.4% during the 1st quarter. ARK Investment Management LLC now owns 8,981,029 shares of the company valued at $652,651,000 after acquiring an additional 1,064,147 shares in the last quarter. Viking Global Investors LP increased its stake in Intellia Therapeutics by 56.3% in Q1. Viking Global Investors LP now owns 2,468,760 shares of the company valued at $179,405,000 after purchasing an additional 889,224 shares in the last quarter. State Street Corp increased its stake in Intellia Therapeutics by 30.2% in Q1. State Street Corp now owns 2,397,527 shares of the company valued at $174,228,000 after purchasing an additional 556,076 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in Intellia Therapeutics by 14.7% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,753,903 shares of the company valued at $327,714,000 after purchasing an additional 353,970 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Intellia Therapeutics by 415.8% in the 1st quarter. Citigroup Inc. now owns 338,786 shares of the company valued at $24,620,000 after purchasing an additional 273,107 shares in the last quarter. Institutional investors and hedge funds hold 85.89% of the company’s shares.

Intellia Therapeutics Company Profile

(Get a rating)

Intellia Therapeutics, Inc, a genome editing company, is focused on developing therapies. The Company’s in vivo programs include NTLA-2001, which is in a Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, plus other liver-focused programs including hemophilia A and hemophilia B, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency .

Featured articles

Stock Target Advisor logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ: NTLA)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Intellia Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Intellia Therapeutics wasn’t on the list.

Although Intellia Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Previous "A Map for the Missing", by Belinda Huijuan Tang
Next Analysts Set Baytex Energy Corp Price Target (TSE:BTE) at CA$8.18